{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:54:25Z","timestamp":1774284865038,"version":"3.50.1"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Palbociclib (PBB) is an oral cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor approved for the treatment of HR+\/HER2\u2212 breast cancer. However, poor adherence and limited tolerability of oral administration often compromise its therapeutic effectiveness, especially in palliative care for metastatic conditions. Dose reductions are frequently required to manage toxicity, but lower doses can still provide effective tumour control with reduced neutropenia risk, thereby improving quality of life and progression-free survival. Developing a long-acting injectable (LAI) formulation of PBB offers significant advantages for sustained therapy in advanced-stage cancer management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study focuses on dose selection, release profile optimisation, and the design of sterile PBB-loaded PLGA microsphere suspensions for intramuscular (IM) administration using physiologically based pharmacokinetic (PBPK) modelling and simulations. The PBPK model, developed and validated with data from oral and intravenous routes, enabled the prediction of IM pharmacokinetics. Clinical target product profiles were defined based on IC50 and minimum steady-state concentration (Css, min).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>The dose optimisation study revealed that the rational selection of dose for both strengths, with an optimised sustained-release profile (Target 2, showing minimal initial burst and controlled release reaching ~55% by day 10.5 and\u00a0~90% by day 21), achieved the desired clinical quality target product profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The developed model will further support polymer selection, specification setting, and drug-to-polymer ratio. Incorporating PBB\u2019s physicochemical properties and host response helps guide rational formulation design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgag028","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:57:57Z","timestamp":1774281477000},"source":"Crossref","is-referenced-by-count":0,"title":["In silico designing of palbociclib loaded PLGA long-acting intramuscular injection for palliative therapy of HR+\/HER2\u2212 metastatic breast cancer"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2015-8649","authenticated-orcid":false,"given":"Rutuja","family":"Suryawanshi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hajipur, Export Promotion Industrial Park (EPIP) , Zandaha Road, NH322, Hajipur, Bihar 844102 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8802-0089","authenticated-orcid":false,"given":"Anumol","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hajipur, Export Promotion Industrial Park (EPIP) , Zandaha Road, NH322, Hajipur, Bihar 844102 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1435-6115","authenticated-orcid":false,"given":"Rajkumar","family":"Malayandi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hajipur, Export Promotion Industrial Park (EPIP) , Zandaha Road, NH322, Hajipur, Bihar 844102 ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026032311575119000_ref1","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors Palbociclib, Ribociclib, and Abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026032311575119000_ref2","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/S41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"2026032311575119000_ref3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-025-02181-3","article-title":"Molecular classification of hormone receptor-positive \/HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026032311575119000_ref4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/curroncol28010066","article-title":"Real-world palbociclib use in HR+\/HER2\u2212 advanced breast cancer in Canada: the iris study","volume":"28","author":"Mycock","year":"2021","journal-title":"Curr Oncol"},{"key":"2026032311575119000_ref5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2017","journal-title":"Gut"},{"key":"2026032311575119000_ref6","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3892\/or.2018.6221","article-title":"Mechanisms of the CDK4\/6 inhibitor Palbociclib (PD 0332991) and its future application in cancer treatment (review)","volume":"39","author":"Liu","year":"2018","journal-title":"Oncol Rep"},{"key":"2026032311575119000_ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212579","article-title":"Palbociclib in metastatic breast cancer: current evidence and real-life data","volume":"8","author":"Serra","year":"2019","journal-title":"Drugs Context"},{"key":"2026032311575119000_ref8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.clbc.2019.06.010","article-title":"Progression-free survival for real-world use of Palbociclib in hormone receptor-positive metastatic breast cancer","volume":"20","author":"Wilkie","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"2026032311575119000_ref9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with Palbociclib plus Fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"key":"2026032311575119000_ref10","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.6.6.6","article-title":"Palbociclib: a new option for front-line treatment of metastatic, hormone receptor\u2013positive, HER2-negative breast cancer","volume":"6","author":"Bowles","year":"2015","journal-title":"J Adv Pract Oncol"},{"key":"2026032311575119000_ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-024-00770-6","article-title":"Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study","volume":"25","author":"Lin","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026032311575119000_ref12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s44313-025-00079-1","article-title":"Diagnosis and management of neutropenia","volume":"60","author":"Il Min","year":"2025","journal-title":"Blood Res"},{"key":"2026032311575119000_ref13","doi-asserted-by":"publisher","first-page":"105400","DOI":"10.1016\/j.msard.2023.105400","article-title":"Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis","volume":"82","author":"Baker","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026032311575119000_ref14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.20892\/j.issn.2095-3941.2020.0069","article-title":"Current Management of Chemotherapy-Induced Neutropenia in adults: key points and new challenges","volume":"17","author":"Ba","year":"2020","journal-title":"Cancer Biol Med"},{"key":"2026032311575119000_ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102810","article-title":"Risk factors for Palbociclib-induced early developing neutropenia in patients with hormone receptor-positive metastatic breast cancer","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026032311575119000_ref16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.breast.2021.11.013","article-title":"Palbociclib dose deductions and the effect on clinical outcomes in patients with advanced breast cancer","volume":"60","author":"Ismail","year":"2021","journal-title":"Breast"},{"key":"2026032311575119000_ref17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12020-017-1270-0","article-title":"Palbociclib inhibits proliferation of human adrenocortical tumor cells","volume":"59","author":"Fiorentini","year":"2018","journal-title":"Endocrine"},{"key":"2026032311575119000_ref18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with Palbociclib, Ribociclib, and Abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"2026032311575119000_ref19","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.2174\/0929867324666170523124441","article-title":"A systematic analysis of physicochemical and ADME properties of all small molecule kinase inhibitors approved by US FDA from January 2001 to October 2015","volume":"24","author":"O\u2019Brien","year":"2017","journal-title":"Curr Med Chem"},{"key":"2026032311575119000_ref20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jconrel.2021.10.022","article-title":"Long-acting injectable donepezil microspheres: formulation development and evaluation","volume":"340","author":"Choi","year":"2021","journal-title":"J Control Release"},{"key":"2026032311575119000_ref21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.33140\/jcrc.05.10.02","article-title":"A case report of palliative Care in a Patient with breast cancer","volume":"5","author":"Elder","year":"2020","journal-title":"J Clin Rev Case Reports"},{"key":"2026032311575119000_ref22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/psp4.13118","article-title":"Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs","volume":"13","author":"Bettonte","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026032311575119000_ref23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025649","article-title":"Long-acting Injectables: current perspectives and future promise","volume":"36","author":"Chaudhary","year":"2019","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2026032311575119000_ref24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.3289","article-title":"Dose optimization informed by PBPK Modeling: state-of-the art and future","volume":"116","author":"Rowland Yeo","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2026032311575119000_ref25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/clpt.2010.298","article-title":"Applications of physiologically based pharmacokinetic (PBPK) Modeling and simulation during regulatory review","volume":"89","author":"Zhao","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2026032311575119000_ref26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/pharmaceutics14010023","article-title":"Two novel palbociclib-resorcinol and palbociclib-orcinol cocrystals with enhanced solubility and dissolution rate","volume":"14","author":"Duan","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026032311575119000_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114906","article-title":"Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure","volume":"164","author":"Roncato","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026032311575119000_ref28","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1021\/acs.molpharmaceut.1c00262","article-title":"Improving dissolution behavior and oral absorption of drugs with pH-dependent solubility using pH modifiers: a physiologically realistic mass transport analysis","volume":"18","author":"Salehi","year":"2021","journal-title":"Mol Pharm"},{"key":"2026032311575119000_ref29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cpdd.356","article-title":"Impact of acid-reducing agents on the pharmacokinetics of Palbociclib, a Weak Base with pH-dependent solubility, with different food intake conditions","volume":"6","author":"Sun","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026032311575119000_ref30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112493","article-title":"Involvement of transporters in intestinal drug-drug interactions of oral targeted anticancer drugs assessed by changes in drug absorption time","volume":"14","author":"Malno\u00eb","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026032311575119000_ref31","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1021\/acs.molpharmaceut.4c01224","article-title":"Investigation of a Palbociclib and Naringin Co-amorphous system to ameliorate anticancer potential: insights on In Silico Modeling, physicochemical characterization, ex vivo permeation, and In vitro efficacy","volume":"22","author":"Kanp","year":"2025","journal-title":"Mol Pharm"},{"key":"2026032311575119000_ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-67126-2","article-title":"Comparative biological activity of Palbociclib and Ribociclib in hormone receptor-positive breast cancer","volume":"14","author":"Lorman-Carb\u00f3","year":"2024","journal-title":"Sci Rep"},{"key":"2026032311575119000_ref33","doi-asserted-by":"publisher","first-page":"1000302","DOI":"10.35841\/2161-0401.22.11.254","article-title":"Organic chemistry\u00a0: current research classification of organic compounds","author":"Mcguire","year":"2022"},{"key":"2026032311575119000_ref34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","article-title":"Applied concepts in PBPK Modeling: how to build a PBPK\/PD model","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026032311575119000_ref35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jcph.792","article-title":"Physiologically based pharmacokinetic Modeling of Palbociclib","volume":"57","author":"Yu","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2026032311575119000_ref36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.oraloncology.2016.05.011","article-title":"Phase I trial of Palbociclib, a selective cyclin dependent kinase 4\/6 inhibitor, In combination with Cetuximab in patients with recurrent\/metastatic head and neck squamous cell carcinoma","volume":"58","author":"Michel","year":"2016","journal-title":"Oral Oncol"},{"key":"2026032311575119000_ref37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00280-017-3246-4","article-title":"Effect of food on the bioavailability of Palbociclib","volume":"79","author":"Ruiz-Garcia","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026032311575119000_ref38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.37667\/pk.2017.1023","article-title":"Food and Drug Administration, Washington (USA): Palbociclib (Ibrance), application number: 207103Orig1s000","volume":"39","year":"2017","journal-title":"Clinical Pharmacology and Biopharmaceutics Review(s)"},{"key":"2026032311575119000_ref39","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026032311575119000_ref40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7324\/JAPS.2022.120505","article-title":"Assessment of pH-shift drug interactions of Palbociclib by in vitro micro-dissolution in bio relevant media: an analytical QbD-driven RP-HPLC method optimization","volume":"12","author":"Patil","year":"2022","journal-title":"J Appl Pharm Sci"},{"key":"2026032311575119000_ref41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1021\/acs.molpharmaceut.2c00545","article-title":"Use of gastrointestinal simulator, mass transport analysis, and absorption simulation to investigate the impact of pH modifiers in mitigating weakly basic drugs\u2019 performance issues related to gastric pH: Palbociclib case study","volume":"20","author":"Kuminek","year":"2023","journal-title":"Mol Pharm"},{"key":"2026032311575119000_ref42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1890\/13-1452.1","article-title":"Model selection for ecologists: the worldviews of AIC and BIC","volume":"95","author":"Aho","year":"2014","journal-title":"Ecology"},{"key":"2026032311575119000_ref43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.idm.2019.12.010","article-title":"A primer on model selection using the Akaike information criterion","volume":"5","author":"Portet","year":"2020","journal-title":"Infect Dis Model"},{"key":"2026032311575119000_ref44","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071317","article-title":"Population pharmacokinetics of Palbociclib and its correlation with clinical efficacy and safety in patients with advanced breast cancer","volume":"14","author":"Courlet","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026032311575119000_ref45","first-page":"53","volume-title":"Clin Drug Investig","author":"","year":"2022"},{"key":"2026032311575119000_ref46","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s40265-017-0832-z","volume-title":"Drugs","author":"Deng","year":"2017"},{"key":"2026032311575119000_ref47","doi-asserted-by":"publisher","first-page":":510","DOI":"10.1111\/jphp.12957","volume-title":"Food for Thought\u00a0: Formulating Away the Food Effect\u00a0\u2013 A PEARRL Review","author":"Griffin"},{"key":"2026032311575119000_ref48","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-015-0379-9","article-title":"Palbociclib: First global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"2026032311575119000_ref49","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1177\/1060028015602273","article-title":"Palbociclib: a novel cyclin-dependent kinase inhibitor for hormone Receptor\u00e3\u00a2\u00e2\u20ac\u0153Positive advanced breast cancer","volume":"49","author":"Mangini","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2026032311575119000_ref50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12070672","article-title":"Food effects on oral dug absorption: application of physiologically-based pharmacokinetic Modeling as a predictive tool","volume":"12","author":"Cheng","year":"2020","journal-title":"Pharmaceutics"},{"key":"2026032311575119000_ref51","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.sjbs.2017.01.032","article-title":"Mechanistic prediction of food effects for compound a tablet using PBPK model","volume":"24","author":"Li","year":"2017","journal-title":"Saudi J Biol Sci"},{"key":"2026032311575119000_ref52","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1634\/theoncologist.2019-0019","article-title":"Palbociclib with Letrozole in postmenopausal women with ER+\/HER2\u2212 advanced breast cancer: hematologic safety analysis of the randomized PALOMA-2 trial","volume":"24","author":"Di\u00e9ras","year":"2019","journal-title":"Oncologist"},{"key":"2026032311575119000_ref53","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jconrel.2020.10.044","article-title":"Formulation composition, manufacturing process, and characterization of poly (lactide- co -glycolide) microparticles","author":"Park","year":"2021"},{"key":"2026032311575119000_ref54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jconrel.2019.05.003","article-title":"Injectable, long-acting PLGA formulations\u00a0: Analyzing PLGA and understanding microparticle formation","volume":"304","author":"Park","year":"2019","journal-title":"J Control Release"},{"key":"2026032311575119000_ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114862","article-title":"Long-acting parenteral drug delivery Systems for the Treatment of chronic diseases","volume":"198","author":"Jindal","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"2026032311575119000_ref56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11523-020-00771-5","article-title":"Impact of dose reduction on efficacy: implications of exposure-response analysis of Palbociclib","volume":"16","author":"Zheng","year":"2021","journal-title":"Target Oncol"},{"key":"2026032311575119000_ref57","doi-asserted-by":"publisher","first-page":"106253","DOI":"10.1016\/j.ejps.2022.106253","article-title":"Lipid based intramuscular Iong-acting Injectables: current state of the art","volume":"178","author":"Wilkinson","year":"2022","journal-title":"Eur J Pharm Sci"},{"key":"2026032311575119000_ref58","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0111","article-title":"A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with Palbociclib","volume":"13","author":"Samjoo","year":"2024","journal-title":"J Comp Eff Res"},{"key":"2026032311575119000_ref59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1208\/s12249-021-01965-4","article-title":"Muscle tissue as a surrogate for In vitro drug release testing of parenteral depot microspheres","volume":"22","author":"Kozak","year":"2021","journal-title":"AAPS Pharm Sci Tech"},{"key":"2026032311575119000_ref60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0168-3659(01)00289-9","article-title":"Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions","volume":"73","author":"Berkland","year":"2001","journal-title":"J Control Release"},{"key":"2026032311575119000_ref61","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jconrel.2007.05.034","article-title":"Effect of acidic pH on PLGA microsphere degradation and release","volume":"122","author":"Zolnik","year":"2007","journal-title":"J Control Release"},{"key":"2026032311575119000_ref62","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0022-3565(25)24466-4","article-title":"One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats","volume":"244","author":"Okada","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"2026032311575119000_ref63","doi-asserted-by":"publisher","first-page":"e38165","DOI":"10.1016\/j.heliyon.2024.e38165","article-title":"The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"2026032311575119000_ref64","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jddst.2018.03.024","article-title":"Effect of size on the in vitro\/in vivo drug release and degradation of Exenatide-loaded PLGA microspheres","volume":"45","author":"Lin","year":"2018","journal-title":"J Drug Deliv Sci Technol"},{"key":"2026032311575119000_ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100394","article-title":"Progress in the application of sustained-release drug microspheres in tissue engineering","volume":"16","author":"Ruan","year":"2022","journal-title":"Mater Today Bio"},{"key":"2026032311575119000_ref66","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/17425247.2022.2105318","article-title":"Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules","volume":"19","author":"Gonella","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"key":"2026032311575119000_ref67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"2026032311575119000_ref68","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-025-00862-x","article-title":"Musculoskeletal adverse events associated with CDK4 \/ 6 inhibitors\u00a0: a real-world study using FDA adverse event reporting system (FAERS) database","volume":"26","author":"Chen","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026032311575119000_ref69","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-022-06518-2","article-title":"Barriers and facilitators to taking CDK4\/6 inhibitors among patients with metastatic breast cancer: a qualitative study","volume":"192","author":"Conley","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2026032311575119000_ref70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2022.1026434","article-title":"Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: a case report","author":"Fontanier","year":"2022"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/3\/rgag028\/67483022\/rgag028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/3\/rgag028\/67483022\/rgag028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:57:58Z","timestamp":1774281478000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/doi\/10.1093\/jpp\/rgag028\/8537605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgag028","relation":{},"ISSN":["2042-7158"],"issn-type":[{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"rgag028"}}